Effectiveness of the SA 14-14-2 Live-Attenuated Japanese Encephalitis Vaccine in Myanmar
<b> </b>Myanmar is an endemic country for the Japanese encephalitis virus (JEV), and the SA-14-14-2 live-attenuated JEV vaccine was first introduced as a catch-up vaccination campaign in 2017. To determine the effectiveness of vaccination by means of neutralizing antibody titers against...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-05-01
|
Series: | Vaccines |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-393X/9/6/568 |
id |
doaj-9562fe97fb0f4a07a30db1420e34e666 |
---|---|
record_format |
Article |
spelling |
doaj-9562fe97fb0f4a07a30db1420e34e6662021-06-01T01:47:03ZengMDPI AGVaccines2076-393X2021-05-01956856810.3390/vaccines9060568Effectiveness of the SA 14-14-2 Live-Attenuated Japanese Encephalitis Vaccine in MyanmarMya Myat Ngwe Tun0Aung Kyaw Kyaw1Khine Mya Nwe2Shingo Inoue3Kyaw Zin Thant4Kouichi Morita5Department of Virology, Institute of Tropical Medicine and Leading Program, Nagasaki University, Nagasaki 852-8523, JapanDepartment of Medical Research, Pyin Oo Lwin Branch, Pyin Oo Lwin 05082, MyanmarDepartment of Virology, Institute of Tropical Medicine and Leading Program, Nagasaki University, Nagasaki 852-8523, JapanDepartment of Virology, Institute of Tropical Medicine and Leading Program, Nagasaki University, Nagasaki 852-8523, JapanMyanmar Academy of Medical Sciences, Yangon 11181, MyanmarDepartment of Virology, Institute of Tropical Medicine and Leading Program, Nagasaki University, Nagasaki 852-8523, Japan<b> </b>Myanmar is an endemic country for the Japanese encephalitis virus (JEV), and the SA-14-14-2 live-attenuated JEV vaccine was first introduced as a catch-up vaccination campaign in 2017. To determine the effectiveness of vaccination by means of neutralizing antibody titers against JEV, a cross-sectional descriptive study was conducted among five to 15-year-old monastic school children in Mandalay, Myanmar. A total of 198 students who had received vaccines were recruited, and single-time investigation of anti-JEV IgG and neutralizing antibodies against wild-type JEV were determined using anti-JEV IgG ELISA and plaque reduction neutralization tests (PRNT<sub>50</sub>). All students 100% (198/198) showed positive results on the anti-JEV IgG ELISA, and 87% (172/198) of the students had neutralizing antibodies against JEV six months after immunization. The geometric mean titers of both IgG antibodies and neutralizing antibodies increased with the participants’ age groups, and statistically significant differences in anti-JEV IgG titers were noted across age groups. In this study, we could not investigate the persistence of neutralizing antibodies as only single-time blood collection was done. This study, which is the first report of JEV vaccination among children in Myanmar, showed similar neutralizing antibody production rates among vaccinated individuals as did studies in other countries.https://www.mdpi.com/2076-393X/9/6/568SA-14-14-2 vaccineJapanese encephalitis viruschildrencatch-up campaignMyanmar |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Mya Myat Ngwe Tun Aung Kyaw Kyaw Khine Mya Nwe Shingo Inoue Kyaw Zin Thant Kouichi Morita |
spellingShingle |
Mya Myat Ngwe Tun Aung Kyaw Kyaw Khine Mya Nwe Shingo Inoue Kyaw Zin Thant Kouichi Morita Effectiveness of the SA 14-14-2 Live-Attenuated Japanese Encephalitis Vaccine in Myanmar Vaccines SA-14-14-2 vaccine Japanese encephalitis virus children catch-up campaign Myanmar |
author_facet |
Mya Myat Ngwe Tun Aung Kyaw Kyaw Khine Mya Nwe Shingo Inoue Kyaw Zin Thant Kouichi Morita |
author_sort |
Mya Myat Ngwe Tun |
title |
Effectiveness of the SA 14-14-2 Live-Attenuated Japanese Encephalitis Vaccine in Myanmar |
title_short |
Effectiveness of the SA 14-14-2 Live-Attenuated Japanese Encephalitis Vaccine in Myanmar |
title_full |
Effectiveness of the SA 14-14-2 Live-Attenuated Japanese Encephalitis Vaccine in Myanmar |
title_fullStr |
Effectiveness of the SA 14-14-2 Live-Attenuated Japanese Encephalitis Vaccine in Myanmar |
title_full_unstemmed |
Effectiveness of the SA 14-14-2 Live-Attenuated Japanese Encephalitis Vaccine in Myanmar |
title_sort |
effectiveness of the sa 14-14-2 live-attenuated japanese encephalitis vaccine in myanmar |
publisher |
MDPI AG |
series |
Vaccines |
issn |
2076-393X |
publishDate |
2021-05-01 |
description |
<b> </b>Myanmar is an endemic country for the Japanese encephalitis virus (JEV), and the SA-14-14-2 live-attenuated JEV vaccine was first introduced as a catch-up vaccination campaign in 2017. To determine the effectiveness of vaccination by means of neutralizing antibody titers against JEV, a cross-sectional descriptive study was conducted among five to 15-year-old monastic school children in Mandalay, Myanmar. A total of 198 students who had received vaccines were recruited, and single-time investigation of anti-JEV IgG and neutralizing antibodies against wild-type JEV were determined using anti-JEV IgG ELISA and plaque reduction neutralization tests (PRNT<sub>50</sub>). All students 100% (198/198) showed positive results on the anti-JEV IgG ELISA, and 87% (172/198) of the students had neutralizing antibodies against JEV six months after immunization. The geometric mean titers of both IgG antibodies and neutralizing antibodies increased with the participants’ age groups, and statistically significant differences in anti-JEV IgG titers were noted across age groups. In this study, we could not investigate the persistence of neutralizing antibodies as only single-time blood collection was done. This study, which is the first report of JEV vaccination among children in Myanmar, showed similar neutralizing antibody production rates among vaccinated individuals as did studies in other countries. |
topic |
SA-14-14-2 vaccine Japanese encephalitis virus children catch-up campaign Myanmar |
url |
https://www.mdpi.com/2076-393X/9/6/568 |
work_keys_str_mv |
AT myamyatngwetun effectivenessofthesa14142liveattenuatedjapaneseencephalitisvaccineinmyanmar AT aungkyawkyaw effectivenessofthesa14142liveattenuatedjapaneseencephalitisvaccineinmyanmar AT khinemyanwe effectivenessofthesa14142liveattenuatedjapaneseencephalitisvaccineinmyanmar AT shingoinoue effectivenessofthesa14142liveattenuatedjapaneseencephalitisvaccineinmyanmar AT kyawzinthant effectivenessofthesa14142liveattenuatedjapaneseencephalitisvaccineinmyanmar AT kouichimorita effectivenessofthesa14142liveattenuatedjapaneseencephalitisvaccineinmyanmar |
_version_ |
1721411601535336448 |